Azelis Weathers Market Storm with Record Cash Flow Amid Profit Drop

ANTWERP, Belgium – February 19, 2026 – Specialty chemicals distributor Azelis Group NV presented a complex picture of its 2025 performance, revealing a company adept at navigating severe market headwinds through stringent financial discipline, even as profitability took a substantial hit. While reported revenue and net profit declined, the company delivered a record-breaking cash performance, underpinning its decision to propose a dividend and continue its strategic acquisition path.

For the full year 2025, Azelis posted revenue of €4.1 billion, a modest 2.4% decrease on a reported basis, though this represented a 1.3% growth when measured in constant currency. The more striking figure was the 40.1% plunge in net profit, which fell to €113 million from €189 million in the prior year. The company attributed the decline to a combination of lower operating profit, a higher effective tax rate, and reduced financial income.

However, the story behind the headline numbers reveals a significant operational success. Azelis generated a remarkable €442 million in free cash flow, a 29.2% increase year-over-year. This resulted in a cash conversion ratio of 106%, the second-highest in the company's history, demonstrating an exceptional ability to turn profits into cash amidst a challenging economic landscape.

A Tale of Two Ledgers

The divergence between profitability and cash flow highlights the effectiveness of Azelis's internal strategies. The decline in adjusted EBITA by 12.7% to €411 million and the accompanying margin contraction were direct results of a challenging sales environment. Gross profit margin shrank by 91 basis points, which the company explained was due to a "negative mix effect," as sales of traditionally higher-margin businesses within its Life Sciences division, such as Personal Care and Flavours & Fragrances, underperformed.

In response, Azelis executed a structural cost-savings plan that delivered annualised savings exceeding the targeted €20 million. More critically, the company focused intensely on working capital management. This disciplined approach led to a reduction in inventory days and a leaner overall working capital position, which was the primary driver behind the surge in free cash flow. This financial resilience allowed the company to reduce its net debt from its peak in September and maintain a leverage ratio of 3.3x by year-end.

"The strong cash flow growth that we delivered in a challenging market is testament to Azelis's robust business model," said Group CEO Anna Bertona in the company's official statement. "This is underpinned by our focus on managing our costs and working capital."

Navigating a Turbulent Global Market

Azelis's performance did not occur in a vacuum. The entire specialty chemicals sector grappled with a difficult 2025, marked by persistent destocking by customers, geopolitical disruptions affecting supply chains, and broad economic uncertainty that dampened demand. Key competitors like IMCD and Brenntag also reported significant pressure on earnings and organic growth, confirming that the headwinds were industry-wide.

Regional performance for Azelis varied significantly. The EMEA (Europe, Middle East & Africa) region was a relative bright spot, with revenue growing 4.4% to €1.9 billion, largely thanks to contributions from recent acquisitions which masked flat organic performance. In contrast, the Americas saw revenue decline by 6.6% to €1.4 billion, suffering from weak demand and customer reluctance to build inventory. The Asia-Pacific (APAC) region faced similar pressures, with revenue falling 9.0% to €805 million, compounded by pricing pressure and tariff-related uncertainties.

Weakness was particularly noted in industrial end markets like CASE (coatings, adhesives, sealants, and elastomers) across multiple regions, reflecting a slowdown in construction and manufacturing activity.

Building for the Future Through M&A and Sustainability

Despite the short-term pressures, Azelis continued to execute its long-term growth strategy through targeted acquisitions and a deepened commitment to sustainability. The company completed four acquisitions in 2025, which together generated over €110 million in revenue in the prior year. These included Solchem in Spain (nutraceuticals), S Amit in India (pharma and agrochemicals), ACEF in Italy (cosmetics and pharma ingredients), and Distona in Switzerland.

These strategic moves strengthen Azelis’s position in high-growth segments and expand its geographic footprint, particularly in the thriving Indian domestic market and key European countries. The acquisitions are expected to provide synergies and bolster the company's innovation capabilities, which were recognized with eight innovation awards during the year.

Alongside its M&A activity, Azelis made significant strides in its sustainability agenda. The company's CDP rating was upgraded to 'A-', placing it in the leadership category for environmental transparency and action. This achievement, part of its 'Impact 2030' program, was complemented by strong ratings from MSCI (AA), EcoVadis (Gold), and Sustainalytics, cementing its reputation as an ESG leader in the industry. The company reported a 16.9% year-on-year reduction in its Scope 1 & 2 emissions, keeping it on track for its 2030 climate targets.

A Cautious but Confident Outlook

Looking ahead, Azelis's management remains cautious, stating that the "timing of market recovery remains uncertain." However, the company's actions signal a firm belief in its strategic direction and financial stability. The Board's proposal to issue a dividend of €0.226 per share is a clear vote of confidence in its ability to generate sustainable cash flow, even in volatile conditions.

Management has reiterated its capital allocation priorities, which balance returning cash to shareholders with prudent de-leveraging and pursuing further value-accretive acquisitions. This balanced approach, combined with its resilient, asset-light business model, positions Azelis to navigate ongoing uncertainty while remaining poised to capture growth opportunities as the market eventually recovers.